Anti-SRP antibody-associated necrotizing myopathy: 2 clinical cases

Necrotizing myopathies are a subtype of autoimmune myopathies characterized by muscle fiber necrosis with minimal infiltration by inflammatory cells on muscle biopsy. This group of myopathies is defined by flaccid palsies due to prima‑ ry skeletal muscle damage as well as extramuscular manifestations such as fever, rash, arthritis, Raynaud’s syndrome and interstitial lung disease. The presence of anti-SRP antibodies is associated with rapidly progressive refractory myositis predominantly affecting limb muscles and axial muscles.

Objective of the work is to analyze the course of severe, refractory to several lines of immunosuppressive therapies anti-SRP associated necrotizing myopathy and to highlight an adequate treatment regime.

Necrotizing myopathy was suspected in patients aged 39 and 56 years with rapidly progressive flaccid tetraparesis on the basis of clinical and anamnestic data, the results of needle electromyography and muscle magnetic resonance imaging, as well as the analysis of myositis-specific and myositis-associated autoantibodies. In both cases, a rapid development of atrophies, marked muscle weakness in the limbs, without involvement of the bulbar musculature, was observed. To achieve effective control of the disease progression, several lines of therapy were required: glucocorticosteroids, intravenous immunoglobulins, methotrexate and rituximab. Our observations are consistent with those in the literature.

Our observations illustrate the clinical course of severe myopathy associated with anti-SRP antibodies. Early initiation of aggressive immunosuppression is crucial to control the disease progression. Treatment and rehabilitation allow achieving significant improvement of the patient’s condition.

1. Malik A., Hayat G., Kalia J.S. et al. Idiopathic inflammatory myopathies: clinical approach and management. Front Neurol 2016;7:64. DOI: 10.3389/fneur.2016.00064

2. Pinal-Fernandez I., Casal-Dominguez M., Mammen A.L. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep 2018;20(4):21. DOI: 10.1007/s11926-018-0732-6

3. McGrath E.R., Doughty C.T., Amato A.A. Autoimmune myopathies: updates on evaluation and treatment. Neurotherapeutics 2018;15(4):976–94. DOI: 10.1007/s13311-018-00676-2

4. Ghirardello A., Borella E., Beggio M. et al. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights 2014;5(3):69–75. DOI: 10.1007/s13317-014-0060-4

5. Betteridge Z., McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2016;280(1):8–23. DOI: 10.1111/joim.12451

6. Antelava O.A. Polymyositis/dermatomyositis: differential diagnosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice 2016;54(2):191–8. (In Russ.). DOI: 10.14412/1995-4484-2016-191-198

7. Rodríguez-Muguruza S., Lozano-Ramos I., Coll-Canti J. et al. Anti-SRP auto-antibodies are not specific for myositis: report of 8 cases. Joint Bone Spine 2017;84(1):103–5. DOI: 10.1016/j.jbspin.2015.12.005

8. Satoh M., Tanaka S., Ceribelli A. et al. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 2017;52(1):1–19. DOI: 10.1007/s12016-015-8510-y

9. Wang L., Liu L., Hao H. et al. Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients. Neuromuscul Disord 2014;24(4):335–41. DOI: 10.1016/j.nmd.2014.01.002

10. Suzuki S., Nishikawa A., Kuwana M. et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis 2015;10:61. DOI: 10.1186/s13023-015-0277-y

11. Allenbach Y., Mammen A.L., Benveniste O. et al. Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscul Disord 2018;28(1):87–99. DOI: 10.1016/j.nmd.2017.09.016

12. Pinal-Fernandez I., Casal-Dominguez M., Carrino J.A. et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis 2017;76(4):681–87. DOI: 10.1136/annrheumdis-2016-210198

13. Lundberg I.E., Tjärnlund A., Bottai M. et al. International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017;76(12):1955–64. DOI: 10.1136/annrheumdis-2017-211468

14. Dimachkie M.M., Barohn R.J., Amato A. Idiopathic inflammatory myopathies. Neurol Clin 2014;32:595–628. DOI: 10.1016/j.ncl.2014.04.007

15. Mammen A. Autoimmune muscle disease. Handbook of clinical neurology. 2016;133:467–84. DOI: 1016/B978-0-444-63432-0.00025-6

16. Kassardjian C.D, Lennon V.A., Alfugham N.B. et al. Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol 2015;72:996–1003. DOI: 10.1001/jamaneurol.2015.1207

17. Kim H.I., Chung S.H., Hwang J.E. et al. Dermatomyositis associated with cancer of unknown primary site. J Korean Med Sci 2007;22 Suppl(Suppl):S174–7. DOI: 10.3346/jkms.2007.22.S.S174

18. Zantos D., Zhang Y., Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994;21(10):1855–9.

19. Hill C.L., Zhang Y., Sigurgeirsson B. et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357(9250):96–100. DOI: 10.1016/S0140-6736(00)03540-6

20. Allenbach Y., Keraen J., Bouvier A.M. et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 2016;139(Pt 8):2131–5. DOI: 10.1093/brain/aww054

21. Pinal-Fernandez I., Parks C., Werner J.L. et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res (Hoboken) 2017;69(2):263–70. DOI: 10.1002/acr.22920

22. Watanabe Y., Uruha A., Suzuki S. et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosur Psychiatry 2016;87:1038–44. DOI: 10.1136/jnnp-2016-313166